Abstract: Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4?-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3?,5?-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1?-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2?-aminopyrimidin-4?-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3?-cycloheptylureido)-N-(5?-methylisoxazol-3?-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.

Abstract: Embodiments of the present disclosure include compositions and methods for treating type 2 diabetes using anti-diabetic steroidal lactones of Withania Coagulans, such as Coagulansin A and derivatives and analogues thereof are described. For example, a method of treating type 2 diabetes in a subject in need thereof, the method comprising administering a therapeutically effective amount of Coagulansin A or a derivative or analogue thereof to the subject is provided. Further described embodiments include compositions and methods of treating muscle atrophy in a subject with type 2 diabetes by initiating regeneration of diseased skeletal muscle myoblasts using anti-diabetic steroidal lactones of Withania Coagulans.

Abstract: Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4?-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3?,5?-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1?-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2?-aminopyrimidin-4?-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3?-cycloheptylureido)-N-(5?-methylisoxazol-3?-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.

Abstract: Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4?-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3?,5?-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1?-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2?-aminopyrimidin-4?-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3?-cycloheptylureido)-N-(5?-methylisoxazol-3?-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.

Abstract: Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4?-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3?,5?-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1?-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2?-aminopyrimidin-4?-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3?-cycloheptylureido)-N-(5?-methylisoxazol-3?-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.

Abstract: Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4?-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3?,5?-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1?-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2?-aminopyrimidin-4?-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3?-cycloheptylureido)-N-(5?-methylisoxazol-3?-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.

Abstract: The pyrimidine derivatives as anti-diabetic agents are chloropyrimidinyl derivatives having the general formula of compound 81, wherein R1 is —N(CH3)CH2CH2OH (compound 81c) or —N(H)CH2CH2OH (compound 81f) or the general formula of compound 82, wherein R2 is —N(CH3)CH2CH2OH (compound 82c) or —N(CH2CH2)2O (compound 82d), as follows: The derivatives may be used for treating diabetes in humans or animals and have demonstrated efficacy, specifically in treating type 2 diabetes. Two methods of synthesizing the pyrimidine derivatives are described herein. The method using microwaves (Method B) is a green method that can provide high yields in a short time and with high purity. The compounds act as GLP-1 receptor agonists and are more potent than conventional drugs. As such, the compounds may be used in lower doses, and, hence, have fewer side effects.

Abstract: Pyrimidine-thiazolidinone derivatives may be used for preventing or treating diseases in humans or animals, and have demonstrated efficacy specifically in treating type-2 diabetes. Methods of synthesizing the pyrimidine-thiazolidinone derivatives, described herein, can provide high yields in a short time and with high purity. The pyrimidine-thiazolidinone derivatives demonstrate improved hypoglycemic activity compared to most anti-diabetic drugs currently available.